2016 American Transplant Congress » Poster Session D: Kidney Immunosuppression: Novel Agents

6:00pm-7:00pm

A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus.

Y. Jung,¹ Y. Kim,¹ S. Kim,¹ H. Shin,¹ H. Rim,¹ H. Rhew.²

6:00pm-7:00pm

Acute Rejection by Belatacept (Bela) Dosing Frequency: Results from a Phase II Study of Kidney Transplant Recipients.

F. Vincenti,¹ G. Blancho,² A. Durrbach,³ G. Grannas,⁴ J. Grinyó,⁵ U. Meier-Kriesche,⁶ M. Polinsky,⁶ H. Zhao,⁶ C. Larsen.⁷

6:00pm-7:00pm

Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.

M. Savic,¹ M. Cruz,² A. Rossi,¹ J. Vella.¹

6:00pm-7:00pm

Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.

F. Oldhafer,¹ M. Hiss,² A. Schwarz,² H. Haller,² G. Einecke.²

6:00pm-7:00pm

Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.

N. Yoshimura, K. Nishimura, K. Akioka, M. Shimazu, K. Nose, T. Nishioka, N. Nakamura, K. Uchida, T. Nakatani, H. Ushigome.

6:00pm-7:00pm

First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.

J. Choi, S. Jordan, A. Vo.

6:00pm-7:00pm

Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.

E. Rhone,¹ R. Gehrau,² S. Bontha,² P. Walker,³ C. Dumur,⁴ D. Maluf,² V. Mas.²

6:00pm-7:00pm

Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.

E. Schrezenmeier,¹ T. Doerner,² O. Staeck,¹ K. Budde,¹ F. Halleck.¹

6:00pm-7:00pm

Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,¹ J. Medina Pestana,² M. del C Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ A. Matas,⁶ T. Wekerle,⁷ J. Grinyó,⁸ U. Meier-Kriesche,⁹ M. Polinsky,⁹ H. Zhao,⁹ A. Durrbach.¹⁰

6:00pm-7:00pm

Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,¹ A. Durrbach,² V. Duro Garcia,³ K. Calderon,⁴ U. Meier-Kriesche,⁴ M. Polinsky,⁴ H. Zhao,⁴ J. Medina Pestana.⁵

6:00pm-7:00pm

Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.

F. Vincenti,¹ J. Medina Pestana,² M. Abouljoud,³ B. Bresnahan,⁴ V. Duro Garcia,⁵ L. Mulloy,⁶ K. Rice,⁷ L. Rostaing,⁸ C. Zayas,⁹ K. Calderon,¹⁰ U. Meier-Kriesche,¹⁰ M. Polinsky,¹⁰ H. Zhao,¹⁰ C. Larsen.¹¹

6:00pm-7:00pm

Post-Trial Experience with Belatacept: A Large Single Center Experience.

A. Adams, C. Garrett, J. Goldstein, R. Zhang, A. Guasch, S. Pastan, R. Patzer, A. Kirk, T. Pearson, C. Larsen.

6:00pm-7:00pm

Preservation of Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.

J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² J. Gadzhyan,¹ E. Lum,¹ U. Reddy,¹ E. Huang,¹ T. Pham,¹ G. Danovitch,¹ E. Reed,² S. Bunnapradist.¹

6:00pm-7:00pm

Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT.

R. Bray,¹ H. Gebel,¹ R. Townsend,² M. Polinsky,² L. Yang,² U. Meier-Kriesche,² C. Larsen.¹

6:00pm-7:00pm

Schisandra Sphenanthera Extract Facilitates Anti-Tuberculosis Treatment Post Renal Transplantation Through Increasing Bioavailability of Tacrolimus.

R. Deng,¹ L. Zhang,¹ L. Liu,¹ H. Fu,² J. Li,¹ Q. Fu,¹ C. Wang.¹

6:00pm-7:00pm

Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.

A. Kumar,¹ Z. Stewart,³ A. Reed,³ D. Orozco,² R. Smith,^1,2 C. Nester,^1,2 C. Thomas.^1,2

6:00pm-7:00pm

Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.

D. Taber, V. Phan, A. Wilton, N. Pilch, H. Meadows, J. Fleming, C. Mardis, A. Mardis, C. Bratton, K. Chavin, J. McGillicuddy, S. Nadig, P. Baliga.

6:00pm-7:00pm

Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.

S. Steinberg,¹ R. Gedaly,² L. Chan,³ A. Langone.⁴